Roche (Basel, Switzerland) will cut 780 production jobs over the next two to three years, according to a story in Wall Street Journal. These layoffs follow plant restructuring that already eliminated 1,152 jobs.
Roche (Basel, Switzerland) will cut 780 production jobs over the next two to three years, according to a story in Wall Street Journal. These layoffs follow plant restructuring that already eliminated 1,152 jobs.
According to the Journal story, Chief Financial Officer Erich Hunziker said the recent cuts involved the sale and closure of factories. The new program will run until 2011.
For the full story see the WSJ web site (subscription required) ref="https://online.wsj.com/article/SB123203531536885863.html?mod=dist_smartbrief">
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.